BCL2 and colorectal carcinoma: For example, MYOT, ASPA, and KIAA2022 were downregulated in CRC [34], the downregulation of ARHGEF37 was associated with a poor prognosis in CRC [35], higher expression levels of BCL-2 were correlated with a better survival prognosis in CRC [36], and PPARGC1A was a negative predictor for CRC prognosis [37].